Kornimate/medical-research-clean huggingface dataset:
repair of oronasal fistula using interpositional buccal pad of fat as a free graft in a cleft palate patient

Conditions: Cleft Palate

Summary: 18 cleft palate patients had residual oronasal fistula included in this study divided randomly to two groups group i (control group): the fistula was repaired using two layers (oral and nasal layers) group ii (study group): the fistula was repaired using two layers (oral and nasal layers ) with interpositional free buccal pad of fat graft between two layers

18 cleft palate patients had residual oronasal fistula included in this study devided randomly to two groups group i (control group):the fistula was repaired using two layers nasal layer:closed by turn-in flaps, taken from around the margins of the fistula by making incision around margins of distance slightly larger than half of diameter of fistula bilaterally, then closed by inverted interrupted suture vicry l 4/0. oral layer:(bardach two-flap palatoplasty) was used and raised on opposite sides of the cleft palate and brought together in the midline to create a continuous palate group ii (study group): the fistula was repaired using two layers (oral and nasal layers ) as group i with buccal pad of fat free graft was taken through veastibular incision at zygomatic buttress then blunt dissection to get buccal fat which was released from its pedicle and inserted between oral and nasal layers.

Eligibility criteria:
inclusion criteria: * cleft palate patients with oro-nasal fistula fistula in hard palate exclusion criteria: * syndromatic patients

Keywords: oro-nasal fistula cleft palate buccal pad of fat free graft
study of guselkumab in skin of color participants with moderate-to-severe plaque and/or scalp psoriasis

Conditions: Plaque Psoriasis; Scalp Psoriasis

Summary: the purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-to-severe body psoriasis or predominant moderate-to-severe scalp psoriasis by assessing improvements in the signs and symptoms of psoriasis.


Eligibility criteria:
inclusion criteria: * have a diagnosis of plaque psoriasis (with or without psoriatic arthritis \[psa\]) for at least 6 months before the first administration of study drug * self-identify as non-white or non-caucasian * be a candidate for phototherapy or systemic treatment for psoriasis * have an involved body surface area (bsa) greater than or equal to (\>=) 10 percent (%), psoriasis area and severity index (pasi) \>=12, investigator global assessment (iga) \>=3 at screening and at baseline (cohort a), or have a scalp surface area \>=30%, psoriasis scalp severity index (pssi) \>=12, scalp specific investigator global assessment (ss-iga) \>=3, and one plaque outside of the scalp at screening and at baseline (cohort b) * agree not to receive a live virus or live bacterial vaccination during the study, or within 12 weeks after the last administration of study intervention * agree not to receive a bacillus calmette-guérin (bcg) vaccination during the study, and within 12 weeks after the last administration of study intervention exclusion criteria: * has a nonplaque form of psoriasis (example: erythrodermic, guttate, or pustular) * has received ustekinumab, ixekizumab, secukinumab, or brodalumab within 12 weeks of first dose of study drug * has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances * participant has known allergies, hypersensitivity, or intolerance to guselkumab or its excipients * has or has had a serious infection (example: sepsis, pneumonia or pyelonephritis), or has been hospitalized or received intravenous antibiotics for an infection during the 2 months before screening
airway inflammation in congenital diaphragmatic hernia patients

Conditions: Congenital Diaphragmatic Hernia

Summary: we propose to examine congenital diaphragmatic hernia (cdh) patients for evidence of airway inflammation as a first step to characterize the reported bronchodilator responsiveness. airway biopsy studies are invasive and thus we propose to perform induced sputum studies to document the amount and type of inflammation present. another ancillary non-invasive measure of airway inflammation that we will use is exhaled nitric oxide (no). the primary objective of this study is to determine if cdh patients have any evidence of airway inflammation. the hypothesis of this study is that children with cdh do not have evidence of airway inflammation associated with bronchodilator responsiveness. based on this information, treatment for cdh patients will hopefully be more accurate and appropriate for their specific needs.


Eligibility criteria:
inclusion criteria: * 6 - 18 years of age at enrolment * clinically stable at enrolment * attending follow-up in the cdh clinic at sickkids exclusion criteria: * unable to perform pulmonary function testing * clinically unstable at enrolment * known hypersensitivity to salbutamol

Keywords: congenital diaphragmatic hernia airway inflammation asthma hypersaline pediatrics
randomized multicenter study of 5 vs 6 weekly fraction of rt in the treatment of scc of the head and neck

Conditions: Carcinoma, Squamous Cell

Summary: randomized multicenter study of 5 vs 6 weekly fraction of rt in the treatment of scc of the head and neck


Eligibility criteria:
inclusion criteria: * patients with scc of the head and neck

Keywords: randomized multicenter study of 5 vs 6 weekly fraction of rt in the treatment of scc of the head and neck
(1,3)-β-d-glucan based diagnosis of invasive candida infection in sepsis

Conditions: Severe Sepsis; Septic Shock

Summary: this prospective randomized multicenter study evaluates whether the decision to prescribe antifungals guided by (1,3)-β-d-glucan in comparison to standard of care shortens time to antifungal therapy and reduces mortality in patients with severe sepsis or septic shock and a high risk of invasive candida infection.

(1,3)-β-d-glucan is a component of the cell wall of many fungi including candida spp. and is present in the blood of patients with invasive candida infection (ici). several studies showed a good diagnostic accuracy (1,3)-β-d-glucan in predicting ici. however, others have challenged (1,3)-β-d-glucan as a diagnostic tool in critically ill patients as many substances used in the intensive care unit might affect the results of the assay. the goal of this study is to investigate whether (1,3)-β-d-glucan can early identify sepsis patients in need of antifungal therapy. patients randomized to the standard of care group receive antifungals depending on microbiological results according to current guidelines. patients randomized to the bdg group receive antifungals depending on the (1,3)-β-d-glucan plasma concentration on day 1 and day after diagnosing sepsis. therapy may be modified according to microbiological results.

Eligibility criteria:
inclusion criteria: * severe sepsis or septic shock * onset of sepsis no longer than 24 hours * increased risk of invasive candida infection with at least one of the following criteria: * total parenteral nutrition ≥48 hours * abdominal surgery within the last 7 days * antimicrobial therapy for at least 48 hours within the last 7 days * acute or chronic renal failure with renal replacement therapy * age ≥18 years * informed consent of the patient or legal representative or delayed consent process is started if patient is incapable of giving informed consent and no legal representative is available. exclusion criteria: * pregnant or lactating women * ongoing invasive candida infection * systemic antifungal therapy * liver cirrhosis child c * cardiopulmonary bypass within the last 4 weeks * treatment with immunoglobulins within the last 14 days * immunosuppression (solid organ transplantation, aisa, leukopenia) * participation in another intervention study * no commitment to full therapy (i.e. dnr order) * infauste prognose aufgrund von nebenerkrankungen * kin to or colleague of study personnel

Keywords: sepsis invasive candida infection biomarker (1,3)-β-d-glucan antifungal therapy intensive care medicine critically ill
sensory profile and early clinical signs of calm room users

Conditions: Psychotic Disorders; Personality Disorders; Mood Disorders

Summary: this descriptive study aims primarily to characterize the sensory profile of patients in a closed psychiatric hospital unit who use a calming room. the main questions it aims to answer are : * could sensory information processing disorders be the cause of distress and tension in these patients? * could users of the calming room present extreme sensory processing profiles, characterized by either hypersensitivity or hyposensitivity ? participants will answer a survey to determine their the sensory profile. participants can already use the calming room as part of their regular medical care and they will answer surveys before and after each use.


Eligibility criteria:
inclusion criteria: * gender and age: male or female, aged 18 to 65 * hospitalization: admitted to the closed hospitalization unit for less than 10 days * social security: affiliated or beneficiary of a social security system * consent: free, informed, and written consent, signed by the participant and/or their legal representative (for participants under protection measures) and the investigator (at the latest on the day of inclusion and before any research-related examination). exclusion criteria: * inability to understand information related to the study * proven sensory disability * dementia * pregnancy * lack of social protection * previous participation in this research protocol (in the case of a new hospitalization) * expression abilities incompatible with completing the aasp scale (e.g., french language comprehension issues, mute individuals, patients in restraint and/or therapeutic isolation)

Keywords: calm room psychotic disorders sensory profile mood disorders personality disorders
incidence of caries in smoking and smokeless tobacco

Conditions: DENTAL CARIES

Summary: the following observational study evaluates incidence of caries in smoking and smokeless tobacco based on habit history by clinical examination and dmft index.

dental caries is an irreversible microbial disease of the calcified tissues of the teeth, characterized by demineralization of the inorganic portion and destruction of the organic substance of the tooth, which often leads to cavitation. it is a complex and dynamic process where a multitude of factors influence and initiate the progression of disease. there are practically no geographic areas in the world whose inhabitants do not exhibit some evidence of dental caries. it affects persons of both genders in all races, all socioeconomic strata and every age group. likewise, there is strong evidence that tobacco use has numerous negative effects on oral health, for example staining of teeth, dental restoration, development of oral diseases. a biologically reasonable explanation for an association between chewing tobacco use and dental caries may be the presence of higher levels of fermentable sugars in chewing tobacco products which can stimulate the growth of carcinogenic bacteria. the decreased buffering effect possible lower ph of smokers saliva and higher number of lactobacilli and streptococcus mutans group may indicate an increased susceptibility to caries in smokers. on the other hand, there are researches which conclude that presence of extrinsic tobacco stains appear to provide a protective effect from caries.

Eligibility criteria:
inclusion criteria: * patients who are willing for the study. * a positive history of dental caries in smokers and smokeless tobacco. * patients with caries not under any treatment of the same. exclusion criteria: * unwilling patients who do not want to be a part of the study. * patient with fluorosis.

Keywords: dental caries tobacco users smokers smokeless tobacco chewers
post-cesarean analgesia with epidural morphine following epidural 2-chloroprocaine

Conditions: Physiological Effect of Drugs; Morphine; Analgesics; Analgesics, Opioid; Central Nervous System Depressants; Narcotics

Summary: the purpose of this study is to show that the effect of 3% 2-chloroprocaine prior to epidural morphine administration will be not inferior to the effect of epidural 2% lidocaine with 1:200,000 epinephrine on total opioid use for 24h


Eligibility criteria:
inclusion criteria: * pregnant patients * live singleton pregnancy exclusion criteria: * bmi \>40 * obstructive sleep apnea * drug abuse * chronic pain * chronic opioid use * nonfunctioning epidural

Keywords: cesarean delivery c-section chloroprocaine lidocaine morphine post-operative pain post-cesarean analgesia
cardiopulmonary rehabilitation in post-acute covid-19 syndrome

Conditions: Post Acute COVID-19 Syndrome

Summary: in 2022, though the optimized acute medical treatment of covid-19 was determined, patients often experience the sequelae (also known as post-acute covid-19 syndrome, the patients might develop cough, breathlessness, fatigue, weakness, impaired activities of daily livings etc.). until now, there is no consensus for post-acute covid-19 syndrome management. previously, the cardiopulmonary rehabilitation revealed significant benefits in heart failure or chronic obstructive pulmonary disease. the aims of the study are demonstrating the benefits and safety of cardiopulmonary rehabilitations in patients previously admitted to hospital because of covid-19 with sequelae.

purpose: to demonstrate the benefits and safety of cardiopulmonary rehabilitations in patients previously admitted to hospital because of covid-19 with sequelae. methods: the participants will be divided into two groups: one with cardiopulmonary rehabilitations programs under the supervision of therapists 3 times a week, 12 weeks in total with lifestyle modification (experimental group); and the other with lifestyle modification and health education (active-controlled group). before and after the interventions, several endpoints in interested are performed by the physicians or the research assistants, including cardiopulmonary exercise training (cpet), 6-minute-walk-test (6mwt), pulmonary function tests (pft), and quality of life (qol, we plan to use sf-36) questionnaire.

Eligibility criteria:
inclusion criteria: * be willing and able to provide written informed consent and comply with all procedures required by the protocol * be 20 - 80 years of age at the time of signing the informed consent form * diagnosed with covid-19 with pcr and admitted with at least moderate covid-19 disease (with clinical symptoms or imaging evidence of low respiratory tract involvement) * diagnosed with covid-19 for over 4 weeks but less than 2 years with fatigue, shortness of breath, cough, weakness, or impairments of activities of daily life * able to cooperate with the rehabilitation programs and cycling exclusion criteria: * patients under 20-year-old or over 80-year-old, pregnant, prisoners * patients without national health insurance in taiwan * the patient cannot follow instructions or cycling

Keywords: long covid cardiopulmonary rehabilitation
is the who recommended dose of pralidoxime effective in the treatment of organophosphorus poisoning?

Conditions: Deaths

Summary: to evaluate the effectiveness of pralidoxime, a drug used for treatment of pesticide poisoning (organophosphorous poisonings)

the present study was designed to critically analyze the role of pralidoxime in patients with moderate to severe poisoning by dividing them into two comparable groups in all aspects and using who recommended dose of pralidoxime (30mg/kg bolus i.v over 20 min followed by 8mg/kg/hr continuous infusion). this dose and continuous infusion protocol is more likely to maintain adequate blood concentrations of pralidoxime throughout 24 hours and thus would avoid any failures in effectiveness of pralidoxime because of inconsistent blood levels.

Eligibility criteria:
inclusion criteria: history of alleged organophosphorus intake age \> 14 years \< 60 years clinical signs and symptoms of organophosphorus poisoning. exclusion criteria: \ 60 years of age known pregnancy pralidoxime administration at the transferring hospital carbamate poisoning any chronic illnesses ≥ 12 hour interval from time of poisoning to initiation of treatment pre-hospital cardiac or respiratory arrest.

Keywords: pralidoxime, atropine, organophosphorous poisoning.
valsartan and amlodipine compared to losartan and amlodipine in hypertensive patients

Conditions: Essential Hypertension

Summary: hypertensive patients with moderate hypertension have a risk to develop cardiovascular events of 15-20% over a period of 10 years. it is important to reach quickly the advised target, but often this result can be obtained with a combination therapy. some evidences demonstrate sartans and calcium channels blockers can be very useful and safe, but it is also important to verify which association can give side effects or give some pharmacokinetic interactions that can negatively influence the clinical combination efficacy.


Eligibility criteria:
inclusion criteria: * diastolic blood pressure in sitting position 100 to 109 mmhg and systolic blood pressure \> 140 mmhg at the end of the selection period exclusion criteria: * type 2 diabetes mellitus * heart failure * ami in the previous 6 months * angina pectoris * secondary hypertension * malignant hypertension * women child-bearing potential * women who are pregnant and lactating * suspected history of allergy to the sartans or calcium channels blockers
multimodal ct examination in stroke mimics diagnosis

Conditions: Stroke Mimics

Summary: the proposed project is a multicentre prospective observational clinical research focused on refining multimodal computer tomography (ct) diagnostics in stroke mimics. the main aim is to accurately identify sm in order to minimize the risk of receiving inappropriate treatment and possible development of complications, which can have a negative impact on the patient´s health. the project includes an analysis of pharmacoeconomic parameters. it will examine saved costs in the case of non-administration of unindicated treatment and it will compare the number of adverse events related to the administration of unindicated treatment in patients diagnosed with sm.

the project has been designed as a prospective multicentre observational clinical research with applied outcomes leading to an improved provision of healthcare and healthcare costs. all patients older than 18 years admitted with suspected stroke will be included in the project. the project will be implemented in 2 hospitals in the czech republic, namely the university hospital in ostrava and the hospital in české budějovice. the analyses will be performed at the university of ostrava. the primary objective of the project is to refine hospital diagnostics through the use of multimodal brain imaging (non-contrast ct (ncct), ct angiography (cta), and ct perfusion (ctp)) at hospital admission. the expected difference is at least 10% more patients with sm in the group diagnosed by the multimodal ct examination when compared to the group diagnosed with ncct or ncct/cta. the primary objective is to demonstrate the specificity and sensitivity of multimodal brain imaging (ncct, cta, and ctp) when compared to the use of ncct or ncct/cta in the acute diagnostics of sm in patients with a sudden focal neurological deficit (minimum 1 point on the national institutes of health stroke scale - nihss) within 24 hours from the onset of symptoms. in addition to the importance of ctp in the diagnosis of stroke mimics, we will also analyze the significance of other clinical data. the secondary objective is to compare the economic indicators and costs that will be saved by not providing inadequate treatment to patients with sm.

Eligibility criteria:
inclusion criteria: - an acute focal neurological deficit (minimum 1 point on the national institutes of health stroke scale - nihss) within 24 hours from the onset of symptoms exclusion criteria: * the last period of normality is unknown prior to multimodal ct examination * the last period of normality is \>24 hours prior to multimodal ct examination * the diagnostic evaluation is incomplete * a final neurologic diagnosis cannot be determined

Keywords: stroke mimics neurological disorders cerebrovascular accident brain disorders computer tomography ct angiography non-contrast head computed tomography intravenous thrombolysis national institutes of health stroke scale
thyroid disease in pregnancy: case finding versus universal screening

Conditions: Thyroid Disease; Pregnancy

Summary: the purpose of this study is to determine whether treatment of thyroid disease during pregnancy decrease the incidence of adverse outcome, and to compare the impact of universal screening versus case finding strategy in detecting thyroid dysfunction

thyroid disease during pregnancy has been associated with multiple adverse outcomes including miscarriage, preterm delivery, postpartum thyroiditis and decreased iq in the offspring. whether or not all women should be screened for thyroid disease during pregnancy (universal screening), screening should be confined to women at high risk for thyroid disease (case finding), or no screening should occur is controversial. for this purpose, pregnant women in the first trimester are randomly assigned to the screening group or case finding group. all women in the screening group and high-risk women in the case finding group are immediately tested for ft4, tsh and tpo antibodies. low-risk women in the case finding group have their sera tested postpartum. levothyroxine or ptu are given in hypothyroid and hyperthyroid women respectively. outcome measure: total number of adverse events occurring during pregnancy and in the neonatal period controlling for clustering of outcomes within women.

Eligibility criteria:
inclusion criteria: * pregnant women * within 11 week of gestation exclusion criteria: * already known thyroid disease

Keywords: thyroid pregnancy
rehab fontan failure: a trial of cardiac rehabilitation

Conditions: Heart Failure Congenital; Single-ventricle

Summary: the goal of this clinical trial is to compare the impact of cardiac rehabilitation on fontan failure patients' exertional tolerance, frailty, and quality of life. 1. among patients with fontan failure, will cardiac rehabilitation increase average daily steps compared to usual care? 2. among patients with fontan failure, will cardiac rehabilitation improve exertional tolerance (as measured by cardiopulmonary exercise testing), frailty, and self-reported quality of life metrics compared to usual care?

rehab fontan failure is a a multi-center, non-blinded, randomized clinical trial evaluating the effect of cardiac rehabilitation compared to usual care on exercise tolerance among adults with fontan failure. eligible study subjects will be identified from clinical chart review and study informational fliers will be sent to adult congenital heart disease (achd) cardiologists at all centers. fontan failure patients being evaluated for outpatient care at achd centers and meeting eligibility criteria will be enrolled and randomly assigned to either cardiac rehabilitation or usual clinical care.

Eligibility criteria:
inclusion criteria: * fontan failure, defined as history of a fontan procedure and at least one of the following: systemic ventricular ef \<50% (by echocardiography, cardiac magnetic resonance imaging, or computer tomography), protein losing enteropathy, plastic bronchitis, chronic loop diuretics prescribed by achd cardiologist, and/or peak vo2 \< 50% predicted (by friend equation) * age \>= 18 years old exclusion criteria: * inotrope-dependence * symptomatic, uncontrolled arrhythmias * pregnancy * contraindication to cardiac rehab or already enrolled in cardiac rehabilitation * inability to comply with the protocol * recent (\<3 months) planned fontan pathway percutaneous or surgical intervention * resting hypoxemia with baseline oxygen saturation \<80%

Keywords: fontan single ventricle cardiac rehabilitation